Therapeutic Vaccines: The Global Market
Report Highlights
-
The total worldwide market for therapeutic vaccines is expected to reach $137 million in 2010. With increased product introductions, this market is expected to reach nearly $3.1 billion in 2014, a compound annual growth rate (CAGR) of nearly 118%.
-
The worldwide market for therapeutic cancer vaccines was worth $137 million in 2010. This market is expected to increase at a compound annual growth rate of 115% to reach an estimated $2.9 billion in 2014.
-
Addiction treatments are expected after 2012. These therapeutic vaccines are forecast to be worth $77 million in 2013 and $135 million in 2014, a compound annual growth rate (CAGR) of more than 100%.
INTRODUCTION
STUDY GOALS AND OBJECTIVES
BCC’s goal in conducting this study was to determine the current status of the therapeutic vaccines industry and assess its growth potential over a 5-year period from 2010 to 2015. Only a handful of such therapeutics has entered clinical use as of the beginning of 2010. For each therapeutic vaccine on the market and almost all therapeutic vaccines in mid-to-late stages of development, we have examined where they stand in the drug development process, major challenges to their approval or market success, achievements and, where applicable, the projected market for each of these drugs through 2014.
We were particularly interested in up-and-coming therapeutic vaccines in phase II or III clinical trials. We identify the leading candidates for therapeutic vaccines by disease application and also vaccine technology. In some cases we discuss notable vaccines that failed in clinical testing.
Our key objective is to present a comprehensive analysis of the current therapeutic vaccines market and its future direction.
REASONS FOR DOING THIS STUDY
A period of dynamic growth in the therapeutic vaccines market is expected with the rollout of eight new products before 2015 to not only treat cancer, but also to address nicotine addiction. Various approaches are being used to develop vaccines that boost the immune response to cancerous cells. They will add a powerful new component to standard cancer treatments. Further back in the pipeline, therapeutic vaccines are also in development to treat infectious diseases such as the Human Immunodeficiency Virus (HIV), neurological disorders such as Alzheimer’s disease, autoimmune disorders such as rheumatoid arthritis and multiple sclerosis, and other conditions such as hypertension.
INTENDED AUDIENCE
We have compiled a detailed description of therapeutic vaccines in phase I, II, and III stages of clinical development. The study includes technological descriptions and challenges, applications, major players, international aspects, and projected growth for some of these therapeutic vaccines through 2014.
This study will be of interest to members of the pharmaceutical, healthcare, and biotechnology industries. It will also be a valuable resource for investors in the biotechnology and pharmaceutical sectors. It is written in such a way as to be accessible to the businessperson while maintaining a high level of technical detail.
SCOPE OF REPORT
At the beginning of 2010, there only were two participants with dedicated therapeutic vaccines actively being sold on the worldwide market. Therefore, the emphasis of this report is on the 113 therapeutic vaccines in various stages of development, the companies poised to introduce products during the forecast period, and how these introductions will play out in terms of the competitive environment.
Special focus is placed on how new products and technologies are likely to define market leaders in the therapeutic vaccine arena. Profiles are provided of companies projected to have therapeutic vaccine products on the market during the forecast period and on companies with rich therapeutic vaccine pipelines.
Included in this report are forecasts by product segment and indications from 2009 through 2014, including supporting analyses for projections.
Trends are assessed based on projected sales of new products being introduced, competitive advantages of emerging technologies as well as other factors such as increases in the prevalence of certain diseases.
The study is arranged to offer an overview of the therapeutic vaccines market, including regulatory issues, and accompanied by detailed analyses and forecasts by product. Profiles of the many emerging competitors in this sector provide a comprehensive assessment of the various products and technologies entering this market as well as marketing strategies being used to gain a competitive edge.
METHODOLOGY
The market assessments provided have been assembled based on publicly available information through 2010-01-15. The base year for this report is 2009 and forecast data are provided through 2014 (to 2015). Market figures are based on current dollars, and inflation is not computed into the projection figures. Interviews were also used to adjust market size estimates as well as to formulate market projections.
The field of therapeutic vaccine development is still immature and the reader is cautioned to use the report data as a guide to assess trends, developments, and challenges that the industry faces.
INFORMATION SOURCES
The information contained in this report has been assembled from both primary and secondary data. Primary research was conducted via in-person, telephone, and e-mail interviews with selected industry professionals, research scientists, and laboratory heads to discover the most recent developments in their fields of interest. Secondary data was collected via a comprehensive search of the scientific, peer-reviewed literature, clinical trial reports and databases, industry trade media, company websites, annual reports, and industry press releases.
AUTHOR’S CREDENTIALS
Brian Lawler has several years of experience working as an analyst covering the pharmaceutical and biotechnology industries. Trained at the University of Southern California, he holds a B.A. degree in economics.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
- Examine BCC’s complete catalog of Market Research Reports and place direct orders
- Subscribe to BCC’s industry newsletters
- Read announcements of recently published reports and newly launched newsletters
- Register for BCC’s well-known conferences
- Request additional information on any BCC product
- Take advantage of special offers
DISCLAIMER
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or from its use.
Frequently Asked Questions (FAQs)
Report Highlights
-
The total worldwide market for therapeutic vaccines was $8.1 million in 2004. With increased product introductions, this market is expected to top $4 billion in 2010.
-
Currently, only products for the treatment of cancer are available.
-
Addiction treatments are expected after 2005, but cancer treatments will continue to dominate.
-
The market and growth for these vaccines will mimic that of innovative prescription pharmaceuticals rather than prophylactic vaccines.
-
It is expected the U.S. will be the primary market. Europe will follow closely behind and Japan, while historically a very small market for prophylactic vaccines, is expected to be a major purchaser.